

Application News

No. C143

Liquid Chromatograph Mass Spectrometry

Simultaneous Analysis of Tyrosine Kinase Inhibitors in Human Blood Plasma with LC/MS/MS

Cancer treatment in recent years employs drugs known as molecular targeted drugs that were developed to target molecules related to the growth, invasion, and metastasis of tumor cells in order to inhibit tumor cell growth.

Lung cancer treatment employs tyrosine kinase inhibitors (TKIs), which target the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and new molecular targeted drugs, referred to as

second and third generation drugs, continue to be developed.

This article introduces an example of simultaneous analysis of EGFR-TKIs, ALK-TKIs, and metabolites in human blood plasma for the purpose of research into pharmacokinetics using the triple quadrupole high performance liquid chromatograph mass spectrometer LCMS-8050.

T. Tsukamoto

Simultaneous Analysis of Four EGFR-TKIs and Three ALK-TKIs

Samples with the standard EGFR-TKIs and ALK-TKIs listed in Table 1 added to a control human blood plasma were deproteinized according to the process in Fig. 1 and the resulting supernatants were submitted

for analysis. MRM measurement with LC/MS/MS can selectively detect target drugs according to their molecular mass and structure (Fig. 2 and Fig. 3).




Fig. 1 Pretreatment Workflow of Blood Plasma Samples




Fig. 2 Precursor Ion and Product Ion of Erlotinib

Table 1 EGFR-TKIs, ALK-TKIs, and Metabolites

	Compound	Molecular formula	Monoisotopic mass [u]	MRM transition m/z
EGFR-TKIs	Afatinib	C ₂₄ H ₂₅ ClFN ₅ O ₃	485.163	486.2 > 371.1
	Erlotinib	C ₂₂ H ₂₃ N ₃ O ₄	393.169	394.2 > 278.1
	OSI-420 *1	C ₂₁ H ₂₁ N ₃ O ₄	379.153	380.2 > 278.1
	Gefitinib	C ₂₂ H ₂₄ ClFN ₄ O ₃	446.152	447.2 > 128.1
	Osimertinib	C ₂₈ H ₃₃ N ₇ O ₂	499.270	500.3 > 72.1
	AZ5104 *2	C ₂₇ H ₃₁ N ₇ O ₂	485.254	486.3 > 72.2
ALK-TKIs	Alectinib	C ₃₀ H ₃₄ N ₄ O ₂	482.268	483.3 > 396.3
	Crizotinib	C ₂₁ H ₂₂ Cl ₂ FN ₃ O	449.119	450.1 > 260.2
	Ceritinib	C ₂₈ H ₃₆ ClN ₅ O ₃ S	557.223	558.2 > 433.1

*1 Erlotinib metabolite, *2 Osimertinib metabolite




Fig. 3 Mass Chromatograms of Human Blood Plasma Samples with Standard Additives

A calibration curve was created from the control blood plasma with standards added and the integrity of accuracy and precision were evaluated. Good linearity was obtained in the set concentration range for all TKIs

and accuracy in the entire range, including the quantitative lower limit, was within 100±15 %. In the same manner, precision (%RSD) was within 15 % and good repeatability was obtained (Table 2).

Table 2 Integrity Evaluation Results for Simultaneous Analysis of EGFR-TKIs, ALK-TKIs, and Metabolites

Compounds	Range (ng/mL)	Accuracy (%)				Precision (%RSD, n=5)			
		LLOQ ^{*1}	Low ^{*2}	Medium ^{*3}	High ^{*4}	LLOQ ^{*1}	Low ^{*2}	Medium ^{*3}	High ^{*4}
Afatinib	5-2000	98.5	103.2	106.3	95.7	12.4	13.9	7.6	7.4
Erlotinib	5-2000	95.1	103.2	102.7	92.3	4.7	5.4	0.8	2.0
OSI-420	5-2000	95.1	104.3	103.4	91.9	9.0	2.7	2.7	3.2
Gefitinib	5-2000	93.0	110.2	103.9	93.5	12.1	6.4	3.4	1.3
Osimertinib	5-2000	94.5	107.0	103.5	93.1	4.6	3.7	2.4	1.9
AZ5104	5-2000	94.7	106.5	102.7	92.5	9.8	6.0	2.7	3.1
Alectinib	5-2000	96.9	101.4	104.0	93.1	13.4	6.3	1.8	1.9
Crizotinib	5-2000	95.4	106.1	106.6	95.3	10.9	11.1	4.1	2.5
Ceritinib	10-2000	94.4	105.2	103.6	91.6	8.0	6.7	1.7	2.8

*1: 5 ng/mL (10 ng/mL for Ceritinib), *2: 10 ng/mL (25 ng/mL for Ceritinib), *3: 100 ng/mL, *4: 1000 ng/mL

■ Analysis of Blood Plasma Specimens

Fig. 4 and Fig. 5 show examples of blood plasma specimen analysis. Erlotinib and the erlotinib metabolite OSI-420 were detected in specimen A and alectinib was detected in specimen B. Like the control blood plasma used to create the calibration curve, no significant

interference by impurities in the blood plasma was observed for either specimen.

This analysis method that uses LC/MS/MS is expected to be utilized as an analysis technique for TKIs in blood plasma specimens.




Fig. 4 Analysis Result of Blood Plasma Specimen A




Fig. 5 Analysis Result of Blood Plasma Specimen B

Table 3 Analysis Conditions

Column	: Shimadzu GLC Mastro C18 (100 mm L. × 2.1 mm I.D., 3 μm)	Injection Volume	: 3 μL
Mobile Phase	: A 10 mmol/L Ammonium formate buffer - water, B Acetonitrile		
Flow Rate	: 0.3 mL/min		
Time program	: B Conc. 10 % (0 min) – 100 % (5 – 7 min) – 10 % (7.01 – 10 min)		
Column Temp.	: 50 °C		
Probe Voltage	: 1.0 kV (ESI-positive mode)	DL Temp.	: 250 °C
Interface Temp.	: 300 °C	Nebulizing Gas Flow	: 3 L/min
Block Heater Temp.	: 400 °C	Drying Gas Flow	: 10 L/min
Heating Gas Flow	: 10 L/min		

<Acknowledgments>

We would like to thank pharmacist Reiko Makihara of the Pharmacy Division at the National Cancer Center Hospital of Japan (National Research and Development Agency) for her significant cooperation in the investigation provided in this document.

- References
- Guidance for Industry : Bioanalytical Method Validation (2001, US FDA)
 - Guideline on Bioanalytical Method Validation in Pharmaceutical Development (2013, Ministry of Health, Labour and Welfare, Japan)

- Notes
- The product described in this document has not been approved or certified as a medical device under the Pharmaceutical and Medical Device Act of Japan.
 - It cannot be used for the purpose of medical examination, treatment or related procedures.
 - The specimens described in this document were all sampled and measured at the National Cancer Center Hospital. Permission was obtained in accordance with proper procedures regarding the publication of measurement data.

First Edition: Mar. 2017



For Research Use Only. Not for use in diagnostic procedure.

This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. Company names, product/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation or its affiliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services. Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

Shimadzu Corporation

www.shimadzu.com/an/